Brent Neidig Sells Shares of USANA Health Sciences

On June 16, 2026, Brent Neidig, the Chief Commercial Officer of USANA Health Sciences, Inc. (NYSE:USNA), sold 5,002 shares of the company's stock. The transaction was valued at approximately $97,288, with an average price of $19.45 per share. This sale is part of ongoing insider activities at the company.

Insider Buying and Selling at USANA Health Sciences, Inc.

Brent Neidig has been actively selling shares of USANA Health Sciences recently. Besides the sale on June 16, he sold 909 shares on June 15 at $20.01 per share and 1,602 shares on June 12 at $20.15 per share. Additionally, Paul Jones, the Chief People Officer, sold 5,561 shares on June 8 and 6,813 shares on May 28, while John Turman Fleming sold 2,450 shares on June 1.

Other Institutional Activity in USANA Health Sciences

Several institutional investors have also adjusted their positions in USANA Health Sciences. BlackRock, Inc. increased its holdings by 78,415 shares, bringing its total to 1,190,416 shares worth about $20.8 million. Nantahala Capital Management, LLC added 225,000 shares, ending with 810,074 shares valued at approximately $14.2 million. In contrast, Renaissance Technologies LLC reduced its position by 129,693 shares, now holding 1,017,630 shares valued at $17.8 million.

USANA Health Sciences Stock Snapshot

Shares of USANA Health Sciences traded near $18.40, with the company having a market capitalization of around $339.7 million. Its P/E ratio stands at 36.8, reflecting a higher valuation compared to its forward P/E of 6.64, suggesting expectations of future earnings growth. The stock's beta is 0.765, indicating lower volatility compared to the market. USANA's 52-week range is between $16.60 and $38.32, with moving averages of $18.73 over 50 days and $20.87 over 200 days.

Recent Earnings

USANA Health Sciences reported revenues of approximately $925.9 million with a slight growth of 0.3%. The company's EPS is $0.50, with a net margin of 0.96% and a return on equity of 1.55%. The next earnings report is scheduled for July 21, 2026.

Analysts Set New Price Targets

Analyst firm D.A. Davidson has maintained a 'hold' rating on USANA Health Sciences, with a recent price target of $36.0 set on February 27, 2025. The consensus target price is $39.0, based on the opinions of one analyst.

About USANA Health Sciences

USANA Health Sciences, Inc., headquartered in Salt Lake City, Utah, develops and markets science-based nutrition, personal care, and skincare products. Operating globally, the company focuses on segments like Core Nutritional and Hiya Direct-To-Consumer. USANA's product lines include nutritional supplements, meal replacements, and skincare regimens. Founded in 1992, the company employs around 1,570 people and is led by CEO Kevin G. Guest.

Bottom Line

Brent Neidig's recent sales are part of broader insider activity at USANA Health Sciences, indicating active management of personal holdings. Investors closely watch insider transactions for potential insights into company performance and sentiment. However, these transactions are historical and may not reflect current intentions. Institutional movements and analyst ratings also provide context for understanding USANA's market position.